Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Mutations and diagnoses among children with elevated plasma C-triol and/or ChT

From: Oxysterol/chitotriosidase based selective screening for Niemann-Pick type C in infantile cholestasis syndrome patients

Patient No.

C-triol

ChT

Mutations identified

Main diagnosis

Group 1

 1

57.8

0

JAG1: c.2384delG (p.G795 fs)

ClinVar SUB5165272

Alagille syndrome

 2

56.6

224

LARS: rs34823161 (c.3077A > G, Tyr1026Cys)

Clinical significance not clear (could not be a cause of an autosomal recessive disorder)

 3

55.0

27

ABCB11: rs72549402 (c.1445A > G, Asp482Gly) and rs1459273753 (c.2178 + 1G > A)

Byler disease, compound heterozygosity confirmed

 4

9.9

126

Not found

Cholestatic liver disease, NOS aetiology

 5

5.8

166

Not found

Cholestatic liver disease, NOS aetiology

 6

48.0

407

Not found

Biliary atresia

 7

16.6

253

Not found

Biliary atresia

 8

9.8

258

Not found

Biliary atresia

 9

7.6

469

Not found

Biliary atresia

Group 2

 10

97.6

1056

NPC1: rs886053665 (c.2090 T > C, Val697Ala) and rs786200877 (c.3591 + 1G > A)

NP-C, compound heterozygosity confirmed

  1. NOS not otherwise specified. Normal central laboratory values for plasma C-triol 0–50 ng/ml and ChT 2.5–100 nM/h/ml